Stocks · News reference

RBC Capital Markets Adjusts United Therapeutics Price Target

Oct 22, 2026, 10:01 PM

RBC Capital Markets has lowered its price target for United Therapeutics Corporation from $708 to $697 while maintaining an Outperform rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 28, 2026, 6:01 PM
United Therapeutics Receives FDA Clearance for Treprostinil-Iloprost Phase 1 Trial
United Therapeutics Corporation has received FDA clearance to proceed with a Phase 1 clinical trial for its treprostinil-iloprost combination therapy for pulmonary arterial hypertension.
UTHR
BenzingaOct 22, 2026, 4:22 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697
UTHR
BenzingaOct 22, 2026, 11:11 AMBenzinga Newsdesk
United Therapeutics Authorizes New $2B Share Repurchase Program Through October 21, 2027
UTHR